Clinical Trials Browser

Phase 2 × Hematologic Neoplasms × Meropenem × Clear all

NCT04983901 2024-11-04

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Phase 2 Completed

100 enrolled 38 charts

Other hematologic neoplasm

Hematologic Neoplasms